Fucidin®
At a Glance
With good efficacy and low resistance of Staphylococcus aureus,5 Fucidin delivers high clinical response rates in a range of bacterial skin infections.1,6
Why Prescribe
Fucidin®?

Kick Staphy
Out!


- A potent antimicrobial, with low resistance to Staphylococcus aureus5
- Fast acting, with a mean healing time of 7.1 days.18
Over 90% of patients with SSTI achieve good results with Fucidin®.18-21

The Fucidin® Family
Select a group to compare

Plain Antibiotic

Antibiotic-Steroid Combination

Active Ingredients
Fusidic acid 20mg/g,
hydrocortisone acetate 10 mg/g
Pack Size
5g
Appropriate in cases where a milder corticosteroid is indicated, and on the face and on children's skin24

Active Ingredients
Fusidic acid 20mg/g, betamethasone as valerate 1mg/g
Pack Size
5g
Indicated in inflammatory dermatoses where bacterial infection is present or likely to occur25

Active Ingredients
Fusidic acid 20mg/g
Pack Size
5g, 15g
Primary & Secondary
skin infections23

Active Ingredients
Sodium fusidate 20mg/g
Pack Size
5g,15 g
Suitable when more occlusive
effect is needed (wet wounds)22
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline,
a wide range of therapies and a pioneering spirit.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to
advance the science of dermatology, setting new standards of care for people with skin conditions.
LEO Pharma is headquartered in Denmark, with a global team of more than 5,500 people, serving 80 million patients in
130 countries. In 2017, the company generated net sales of 1.4 billion euro.
Our Mission
We help people achieve healthy skin
Our Vision
We are the preferred dermatology care partner improving people's lives around the world
- Schofer H & Simonsen L. Eur J Dermatol 2010;20:6-15.
- IMS MAT Q3’18 (ATC D06A Value and Volume Market Share) - Europe Region
- Knight AG et al. Br J Dermatol 1969;81(Suppl 4):88-91.
- Stuttgen G & Bauer E. Drug Res 1988;38:730-735.
- Stratchounski LS, Dekhnich AV, Kretchikov VA, et al. J Chemother.2005;17:54–60.
- Spelman D. J Antimicrob Agents 1999; 12(Suppl 2):S59-S66.
- Long BH. Acta Derm Venereol 2008;Suppl 216:14-20.
- Primary Care Dermatology Society & British Association of Dermatologists. Guidelines for the management of atopic eczema. Available at:
http://www.pcds.org.uk/images/stories/pcdsbad-eczema.pdf. Accessed on 11/1/2019. - Wollenberg A et al. J Eur Acad Dermatol Venereol. 2016;30(5):729-747.
- NICE Guidelines. Treating atopic eczema in children aged 12 and under. Available at: https://pathways.nice.org.uk/pathways/eczema#path=view%3A/pathways/eczema/ treating-atopic-eczema-in-children-aged-12-and-under.xml&content=view-node%3Anodes-bacterial-infection Accessed on 11/1/2019.
- NHS Guidelines. Guidelines for the management of eczema in children under 12 years. Available at: http://www.southwarkdermatology.co.uk/website/X20213/-les/ Guidelines%20for%20the%20management%20of%20eczema%20in%20children%20under%2012yrs%20(Final_July_2015).pdf Accessed on 11/1/2019
- Tay YK et al. Ann Acad Med Singapore. 2016;45:439-450.
- Katayama I et al. Allergology International. 2017;66:230-247.
- Werfel T et al. Allergo J Int. 2016;25:82-95.
- Galli E et al. Ital J Pediatr. 2016;42:26.
- Rigopoulos D & Larios M. Acta Derm Venereol 2008; Suppl 216: 7–13.
- Mistry RD. Pediatric Clinics 2013;60(5):1063-1082.
- Pakrooh H. Curr Med Res Opin. 1978;5(4):289-94.
- Langdon CG, Mahapatra KS. Curr Ther Res. 1990;48(1):174-80.
- Baldwin RJT, Cran¬eld R. Br J Clin Pract. 1981;35(4):157-60.
- White DG et al. J Infect. 1989;18:221-29.
- Fucidin Ointment Prescribing Information
- Fucidin Cream Prescribing Information
- Fucidin H Prescribing Information
- Fucicort Cream Prescribing Information